Physician profile
Daniel T Mcgehee
NPI 1780656975
$830.14
in general payments reported to CMS, 2019-2025
11 companies · $14.73 in 2025
The $14.73 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $63.21 · 2021: $299 · 2022: $137 · 2023: $40.48 · 2024: $123 · 2025: $14.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $178.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $171.63 | 2019-2021 | |
| Rxsight INC | $150.83 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $122.97 | 2024 | Infuse |
| Novartis Pharmaceuticals Corporation | $84.19 | 2020-2021 | |
| Alcon Vision LLC | $77.57 | 2021 | |
| Aerie Pharmaceuticals, INC. | $60.02 | 2019-2021 | |
| Glaukos Corporation | $55.56 | 2021 | |
| The Cameron-Ehlen Group, INC. | $52.16 | 2021 | |
| Abbvie INC. | $21.16 | 2023 | |
| Sight Sciences, INC. | $19.32 | 2023 | Omni Surgical System |
| Astellas Pharma US INC | $14.73 | 2025 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mcgehee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.